Research

Researchers Working on Blood Test to Detect Brain Metastases While Still Treatable


By Gale Smith | August 09, 2017

Houston Methodist cancer researchers are now closer to creating a blood test that can identify breast cancer patients who are at increased risk for developing brain metastasis, and also monitor disease progression and response to therapy in real time.

The discovery of identifying a distinct group of cells in the bloodstream of patients who have breast cancer brain metastases could lead to the creation of more sensitive screening tools.

VIDEO: Dr. Marchetti explains the research

In the Aug. 4 online issue of Nature Communications, a proof-of-concept study led by Dario Marchetti, Ph.D., detected a distinct group of circulating tumor cells (CTCs) associated with brain metastasis. The finding brings cancer researchers closer to understanding how the “seeds” of metastatic disease can thrive in breast cancer patients and cause it to spread to the brain.

“Our research confirmed that CTCs in breast cancer brain metastases are distinct from other circulating tumor cells. Moreover, unlocking the mystery of how these seeds of metastatic disease survive and thrive over a period of years, sometimes decades, is an enigma in cancer,” said Marchetti, senior author and director of the Biomarker Research Program at Houston Methodist Research Institute. “Now we can take this information and develop a more sensitive screening tool to detect metastatic cancer in the blood, possibly even before metastasis is radiologically detectable by MRI.”

Magnetic resonance imaging is the accepted standard-of-care to diagnose breast cancer brain metastasis (BCBM) in patients. However, in most cases, by the time MRI detects the metastatic mass, the cancer has progressed to a stage where few curative treatment options are available, leading to poor overall survival. According to extensive clinical studies, approximately 20 percent of breast cancer patients will develop brain metastasis over their lifetime, and, in general, metastatic disease to the brain is estimated to become the number one cancer killer within the next decade.

“Our lab is the first in this field to perform a comprehensive report of patient-derived circulating tumor cells at the gene expression level, so we now have a clearer picture of the signaling pathways that allows them to establish brain metastases. By comparing the whole genome expression patterns of CTCs isolated from patient blood samples diagnosed with or without BCBM, we uncovered a 126 gene-signature that is specific to these brain metastatic CTCs,” said Debasish Boral, Ph.D., the paper’s first author and a research associate with the Biomarker Research Program at Houston Methodist Research Institute.

This research builds on a 2015 research paper where Marchetti’s lab isolated four distinct circulating tumor cell subsets that were implicated in breast cancer cell dormancy. Viable breast cancer cells can remain dormant in the patients’ bone marrow or other organs like the brain, lungs and liver, even decades after a primary tumor is surgically removed. These scattered cells are often undetectable by traditional clinical tools, making it nearly impossible to detect and treat metastatic disease while still amenable to therapy.

The Houston Methodist researchers are now focused on broadening the study patient population, with the end goal of transforming this information into the development of two kinds of non-invasive liquid biopsies that could be used by treating physicians: a screening method to predict brain metastasis before the disease is detectable by current diagnostic standards (MRI); and another to monitor treatment efficacy in real-time in those patients diagnosed with brain metastasis.

Other researchers collaborating on the Nature Communications paper were: Monika Vishnoi, Haowen N. Liu, Wei Yin, and Marc L. Sprouse (Houston Methodist Research Institute, Houston, TX); Jenny C. Chang (Houston Methodist Hospital, Houston, TX); Antonio Scamardo and David S. Hong (The University of Texas MD Anderson Cancer Center, Houston, TX); and Tuan Z. Tan and Jean P. Thiery (Cancer Science Institute of Singapore, National University of Singapore).

To speak with Dario Marchetti, Ph.D., contact Lisa Merkl, Houston Methodist, at 832-667-5916 or lmerkl@houstonmethodist.org. For more information about Houston Methodist, visit houstonmethodist.org. Follow us on Twitter and Facebook.

———————–
For more information: Molecular characterization of breast cancer CTCs associated with brain metastasis. Nature Communications DOI: 10.1038/s41467-017-00196-1. (Online Aug. 4, 2017) D. Boral, M. Vishnoi, H. N. Liu, W. Yin, M. L. Sprouse, A. Scamardo, D. S. Hong, T. Z. Tan, J. P. Thiery, J. C. Chang, and D. Marchetti.
-30-

Tags | Research



Social Posts

profile_image

Houston Methodist

@MethodistHosp

.@MethodistHosp San Jacinto Hospital celebrated the groundbreaking for the expansion of the Emergency Department. https://t.co/6JgaAAMLhQ

4 hours ago
profile_image

Houston Methodist

houstonmethodist

Houston Methodist San Jacinto Hospital celebrated the groundbreaking for the expansion of the Emergency Department. The expansion will further enhance the range...

4 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

Radiation physicist: “We’re here because cancer has touched us, and we just want to get back at it."… https://t.co/bnu0cwtaUN

4 hours ago
profile_image

Houston Methodist

@MethodistHosp

.@MethodistHosp Research Institute president was appointed to Pope Francis’ Pontifical Academy for Life. Learn more… https://t.co/vc2cWCcJPh

6 hours ago
profile_image

Texas A&M University Health Science Center

TAMUhealthsciences

“Repurposing already-approved blood pressure drugs, in combination with gene therapy, may be the best approach, but there's still more work to be done."

6 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

More Veterans reached with services, supplies through partnership https://t.co/tpaQXw6RPO via #VAntagePoint

7 hours ago
profile_image

University of Houston

@UHouston

RT @UHCougarFB: One in... Congrats @Roberts_52! #HTownTakeover https://t.co/WUPjq1Fxqk

7 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

Today’s #VeteranOfTheDay Army Veteran Henry Filipowicz https://t.co/3TWjDcNATj #ArmyVet

7 hours ago
profile_image

U.S. Department of Veterans Affairs

VeteransAffairs

Today’s #VeteranOfTheDay is Army Veteran Henry Filipowicz. Henry served in World War II and the Korean War. He enlisted in 1942 as an infantryman and fought in...

7 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

Vietnam War Veteran sets up memorial for friends along California highway https://t.co/XAFkqUcv5U via @FoxNews

8 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

Why BRCA1 carrier Linda Phetphongsy underwent a double mastectomy & #breastreconstruction https://t.co/64Rw0Xdt4B… https://t.co/z4tIJ1LjU6

8 hours ago
profile_image

BCMHouston

@bcmhouston

Our researchers are conducting hundreds of clinical trials. Explore the volunteer opportunities available.… https://t.co/dHM3tXEX7x

9 hours ago
profile_image

Baylor College of Medicine

BaylorCollegeOfMedicine

Get your flu questions answered by our experts! http://bit.ly/2DkrEAn #flu

9 hours ago
profile_image

MD Anderson Cancer Center

MDAnderson

Did you know that some cancer treatments can cause changes to your skin? Sometimes these changes are simply cosmetic, but other times they may require attention...

9 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

Our expert on #laryngectomy: “It may take a little more effort, but you can communicate effectively.”… https://t.co/cHEdVnGbO2

10 hours ago